Monoclonal gammopathy of undetermined significance secondary prevention
|
Monoclonal gammopathy of undetermined significance Microchapters |
|
Differentiating Monoclonal gammopathy of undetermined significance from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Monoclonal gammopathy of undetermined significance secondary prevention On the Web |
|
American Roentgen Ray Society Images of Monoclonal gammopathy of undetermined significance secondary prevention |
|
FDA on Monoclonal gammopathy of undetermined significance secondary prevention |
|
on Monoclonal gammopathy of undetermined significance secondary prevention |
|
Monoclonal gammopathy of undetermined significance secondary prevention in the news |
|
Blogs on Monoclonal gammopathy of undetermined significance secondary prevention |
|
Directions to Hospitals Treating Monoclonal gammopathy of undetermined significance |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]; Associate Editor(s)-in-Chief: Omer Kamal, M.D.[3]
Overview
Secondary prevention includes measures to delay the progression of MGUS to active multiple myeloma.
Secondary Prevention
Secondary prevention includes measures to delay the progression of MGUS to active multiple myeloma. Laboratory tests and physical examination are routinely performed. Laboratory testing includes[1]:
References
- ↑ Tate JR, Graziani MS, Mollee P, Merlini G (2016). "Protein electrophoresis and serum free light chains in the diagnosis and monitoring of plasma cell disorders: laboratory testing and current controversies". Clin Chem Lab Med. 54 (6): 899–905. doi:10.1515/cclm-2016-0268. PMID 27107838.